Creative Planning
RAPP

Creative Planning’s Rapport Therapeutics RAPP Stock Holding History

Creative Planning’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$955K Buy
22,918
+7,399
+48% +$272K ﹤0.01% 2673
2026
Q1 		$486K Buy
15,519
+3,307
+27% +$93K ﹤0.01% 3052
2025
Q4 		$371K Buy
12,212
+253
+2% +$7K ﹤0.01% 3092
2025
Q3 		$355K Buy
11,959
+1,357
+13% +$24.2K ﹤0.01% 3015
2025
Q2 		$121K Buy
+10,602
New +$113K ﹤0.01% 3385

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Creative Planning's RAPP Position: Q2 2026 in Review

Creative Planning increased its Rapport Therapeutics (RAPP) stake by 48% in Q2 2026, buying an estimated $272K and bringing the position to 22,918 shares worth $955K. The position accounts for ﹤0.01% of the portfolio, ranked #2673.

Creative Planning first reported a position in RAPP in Q2 2025 and has held it in 5 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Creative Planning held 22,918 shares of Rapport Therapeutics worth $955K as of Q2 2026.
  • Creative Planning bought 7,399 Rapport Therapeutics shares in Q2 2026, an estimated $272K.
  • Rapport Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2673 holding.
  • Creative Planning first reported a position in Rapport Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.